Breast cancer expresses functional NMDA receptors

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 307-314

  North, William G ^a   Gao, Guohong ^a   Memoli, Vincent A ^a   Pang, Roy H ^b   Lynch, Launa ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Woomera Therapeutics Inc   (United States)

Author keywords

Breast cancer; NMDA receptors; Tumor growth; Tumor markers

Indexed keywords

DIZOCILPINE; MEMANTINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DIZOCILPINE MALEATE; GRIN1 PROTEIN, HUMAN; NERVE PROTEIN; NR2B NMDA RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN MCF 7; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENOME SIZE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IC50; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MEMANTINE; MICE; MICE, NUDE; NERVE TISSUE PROTEINS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955659301     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0556-1     Document Type: Article

References (24)

1. North WG, Fay MJ, Du JL, Cleary M, Gallagher JD, McCann FV (1997) Presence of functional NMDA receptors in a human neuroblastoma cell-line. Mol Chem Neuropathol 30:77-94.
2. Danilczuk Z, Ossowska G, Lupina T, Ciesslik K, Zebrowska-Lupina I (2005) Effect of NMDA receptor antagonists on behavioral impairment induced by chronic treatment with dexamethasone. Pharmacol Rep 57:47-54.
3. Carpenter D (2002)NMDA receptors and the molecular mechanisms of excitotoxicity. In: Johnson P, Boldyrev AA (eds) Oxidative stress at the molecular, cellular, and organ levels. Research Signpost, Trivandrum, pp 77-88.
4. Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y, Yoneda Y (2004) Glutamate signaling in peripheral tissues. Eur J Biochem 271:1-13.
5. Sonkusare SK, Kaul CL, Ramarao P (2005) Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Rev 51:1-17.
6. Plosker GL, Lyseng-Williamson KA (2005) Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 23:193-206.
7. Kashiwagi K, Masuko T, Nguyen CD, Kuno T, Tanaka I, Igarashi K, Williams K (2002) Channel blockers acting at N-methyl-Daspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol Pharmacol 61:533-545.
8. Fredriksson A, Danysz W, Quack G, Archer T (2001) Coadministration of memantine and amantadine with sub/suprathreshold doses of L-dopa restores motor behaviour of MPTP-treated mice. J Neural Transm 108:167-187.
9. North WG, Maurer LH, Valtin H, O'Donnell JF (1980) Human neurophysins as potential tumor markers for small-cell carcinoma of the lung: application of specific radioimmunoassays for vasopressin-associated and oxytocin-associated neurophysins. J Clin Endocrinol Metab 51:892-896.
10. North WG, Pai S, Friedmann AS, Fay MJ, Yu X.-M, Memoli VA (1995) Vasopressin gene-related products are markers of human breast cancer. Breast Cancer Res and Treat 34:229-235.
11. North WG (1991) Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease. J Clin Endocrin Metab 73:1316-1320.
12. Moriyoshi K, Masu M, Ishu T, Shigemoto R, Mizuno N, Nakanishi S (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354:31-37. (Pubitemid 21896774)
13. Hess SD, Daggett LP, Crona J, Deal C, Lu C-C, Urrutia A, Chavez-Noriega L, Ellis SB, Johnson EC, Velicelebi G (1996) Cloning and functional characterisation of human heteromeric Nmethyl- D-aspartate receptors. J Pharmacol Exper Therap 278: 808-816.
14. Ahmed SA, Gogal RM Jr, Walsh JE (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170(2):211-224.
15. Silverstein MJ et al (2002) International consensus Conference: Image-detected breast cancer: state of the art diagnosis and treatment. Breast J 8:70-76.
16. Pierce AGE (1969) The cytochemistry and ultrastructure of polypeptide hormone producing cells of the APUD series, and the embryologic, physiologic, and pathologic implications of the concept. J Histochem Cytochem 17:303-313.
17. North WG (2000) Gene regulation of vasopressin and vasopressin receptors in cancer. Exper Physiol 85S:27-40.
18. Roos DH, Puntel RL, Santos MM, Souza DO, Farina M, Nogueira CW, Aschner M, Burger ME, Barbosa NB, Rocha JB (2009) Guanosine and synthetic organoselenium compounds modulate methylmercury-induced oxidative stress in rat brain cortical slices: involvement of oxidative stress and glutamatergic system. Toxicol In Vitro 23:302-307.
19. Longuemare MC, Keung EC, Chun S, Sharp FR, Chan PH, Swanson RA (1996) MK801 reduces uptake and stimulates efflux of excitatory amino acids via membrane depolarization. Am J Physiol 270:C1398-C1404.
20. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Bührer C, Hansen HH, Stryjecka-Zimmer M, Turski L, Ikonomidou C (2005) NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102:15605-15610.
21. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127-135.
22. Kawabe K, Yoshihara T, Ichitani Y, Iwasaki T (1998) Intrahippocampal d-cycloserine improves MK-801-induced memory deficits: radial arm maze performance in rats. Brain Res 814:226-230.
23. Gilbert ME (1988) The NMDA-receptor antagonist, MK-801, suppresses limbic kindling and kindled seizures. Brain Res 463: 90-99.
24. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, Poulsen D, Leone P, Xu R, Dicker BL, Lipski J, Young D (2000) An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science:1453-1460.